Brokerages Anticipate Nabriva Therapeutics AG (NBRV) Will Announce Quarterly Sales of $1.32 Million
Brokerages expect Nabriva Therapeutics AG (NASDAQ:NBRV) to post sales of $1.32 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Nabriva Therapeutics AG’s earnings. The lowest sales estimate is $1.00 million and the highest is $1.70 million. The firm is expected to issue its next quarterly earnings results on Wednesday, November 15th.
On average, analysts expect that Nabriva Therapeutics AG will report full year sales of $1.32 million for the current fiscal year, with estimates ranging from $4.73 million to $6.20 million. For the next year, analysts anticipate that the company will report sales of $6.79 million per share, with estimates ranging from $2.90 million to $10.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Nabriva Therapeutics AG.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($5.83) by $5.29. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.34 million.
Several brokerages have recently weighed in on NBRV. Cantor Fitzgerald restated a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a report on Friday, September 1st. Zacks Investment Research upgraded Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a report on Wednesday, October 11th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Nabriva Therapeutics AG in a report on Monday, August 28th. SunTrust Banks, Inc. upped their price objective on Nabriva Therapeutics AG from $20.00 to $24.00 and gave the company a “buy” rating in a report on Monday, September 18th. Finally, Wedbush restated an “outperform” rating and issued a $21.00 price objective (up previously from $13.00) on shares of Nabriva Therapeutics AG in a report on Monday, September 18th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $18.78.
Shares of Nabriva Therapeutics AG (NASDAQ NBRV) opened at 6.69 on Thursday. The firm has a 50-day moving average price of $8.24 and a 200-day moving average price of $9.67. Nabriva Therapeutics AG has a 12-month low of $3.52 and a 12-month high of $14.10. The firm’s market cap is $179.55 million.
COPYRIGHT VIOLATION WARNING: “Brokerages Anticipate Nabriva Therapeutics AG (NBRV) Will Announce Quarterly Sales of $1.32 Million” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/10/19/brokerages-anticipate-nabriva-therapeutics-ag-nbrv-will-announce-quarterly-sales-of-1-32-million.html.
In related news, major shareholder Vivo Capital Viii, Llc bought 52,631 shares of Nabriva Therapeutics AG stock in a transaction dated Monday, September 18th. The stock was acquired at an average cost of $9.46 per share, with a total value of $497,889.26. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 6,585 shares of the company’s stock in a transaction on Friday, July 28th. The shares were sold at an average price of $10.51, for a total value of $69,208.35. Following the sale, the insider now directly owns 2,391,177 shares of the company’s stock, valued at $25,131,270.27. The disclosure for this sale can be found here. In the last 90 days, insiders bought 57,219 shares of company stock valued at $535,919 and sold 81,585 shares valued at $785,050. Corporate insiders own 2.75% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in NBRV. Wellington Management Group LLP lifted its holdings in shares of Nabriva Therapeutics AG by 9.9% during the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after purchasing an additional 193,951 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in shares of Nabriva Therapeutics AG during the first quarter valued at $1,870,000. Nationwide Fund Advisors lifted its holdings in shares of Nabriva Therapeutics AG by 4.6% during the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after purchasing an additional 7,924 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of Nabriva Therapeutics AG by 19.6% during the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after purchasing an additional 8,650 shares during the last quarter. 50.23% of the stock is owned by institutional investors and hedge funds.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.